Scroll To Top
Search by Speciality

EUROGIN 2013: EUROPEAN RESEARCH ORGANISATION ON GENITAL INFECTION & NEOPLASIA CONGRESS

Palazzo dei Congressi Firenze Fiera # | Florence, ITALY
From 400 to 840 EUR
Event Preview
EXPIRED
This event
is Finished
Title: EUROGIN 2013: EUROPEAN RESEARCH ORGANISATION ON GENITAL INFECTION & NEOPLASIA CONGRESS
Specialty: , Other Specialties
Dates: From Nov, 3, 2013 to Nov, 6, 2013
Location: Florence, ITALY
Type: Congress
Registration Cost: From 400 to 840 EUR
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
Nov
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for Florence, Italy.
General Info
Event Venue:

Palazzo dei Congressi Firenze Fiera #

Florence, ITALY
Palazzo dei Congressi PDF Print E-mail
Located inside the 18th century Villa Vittoria, Palazzo dei Congressi Firenze boasts a prestigious auditorium which can host up to  1,000 people. There is also an exhibiting area of 920 sq m, along with other halls which can host 50, 80 (Sala Onice -Onyx Hall) and 200 people (Sala Verde - Green Hall) respectively, and which are positioned within the 4 floors of the villa. Surrounded by a centuries-old garden, Palazzo dei Congressi and its adjacent Lemon House are located in front of Palazzo degli Affari and are connected to the Fortezza da Basso through a pedestrian square, thus forming a congress & exhibition area which is completely accessible on foot, in the heart of the city. giardino_07-focus-villa The charming interiors of the venue are characterised by a combination of Florentine antique furniture with modern and functionally designed halls. If you want to know the history and the origins of the prestigious Villa Vittoria, home of the Palazzo dei Congressi, click here pdf_button
Visit the Venue to read more
Currency:
EUR
Accreditation:

-

The EUROGIN 2013 congress "HPV at a Crossroads - 30 Years of Research and Practice" is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net

The EUROGIN 2013 congress "HPV at a Crossroads - 30 Years of Research and Practice" is designated for a maximum of 21 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Event Overview
Welcome message:

Dear colleagues and friends of EUROGIN, 

Again this year, the scientific committee of EUROGIN, directed by Dr Joseph Monsonego, is preparing an elaborated programme for all of us, in Florence, Italy, November 3-6. 

Over the years, EUROGIN has become an unavoidable scientific congress. At the beginning, the congresses were held every three years but, with the speed of scientific developments, later their frequency became nearly yearly. Some of us are old enough to remember the 1st EUROGIN congress in 1994. Harald zur Hausen and Maurice Tubiana were honorary presidents, and close to 500 scientists and clinicians participated. HPV-related diseases have surely been one of the areas of greatest progress in medicine. 

An example of rapid progression is vaccine. After the 2003 meeting, one of the conclusions of the congress stated that “Development of prophylactic vaccines for HPV is warranted”. Only five year later, at the 2008 EUROGIN meeting, results of clinical studies demonstrating the efficacy of a vaccine against some types of HPV opened the way to prevention of HPV infections and hopefully of cervical cancer. EUROGIN has been a very important way to spread the good news to physicians and patients all over the world. HPV vaccines are now included in the immunisation programmes of industrialised countries and the main issue is actually reaching the target women. The gap with the low-resource countries, which would most need vaccination, is still evident. However the success of monitored pilot projects in countries like Bhutan or Rwanda and the opening of GAVI to support low-price delivery to the poorest countries are important. On the side of technology, the development of multivalent vaccines is in a very advanced stage. 

A large amount of evidence has been produced about the use of HPV testing for cervical screening and research could define some crucial issues on how to perform it. A large amount of research is however on-going, including the pooled analysis of existing randomised trials, the development of biomarkers, their practical application and their integrated use. New developments of relevant impact for clinical practice are therefore expected for the EUROGIN 2013 conference. A main point is now moving to the practical implementation of HPV-based screening. HPV based screening is now officially recommended in a number of industrialised countries. This however entails facing a number of problems of organisation, communication, monitoring and quality assurance. The recent availability of low-cost and robust HPV tests also opens the perspective of a practical implementation of HPV-based screening in low-resource settings. Comparing how these issues have been approached in different high- and low-resource countries will be one of the purposes of the conference. 

The main issue in the next years will be the integration of vaccination and screening. Massively vaccinated cohorts will soon reach the age of screening and defining an adequate screening policy for them is urgent. On the other hand, the combination of screening and vaccination can be exploited in order to reach a rapid reduction of cervical cancer and to reduce the costs and undesired effects of screening. Hypotheses in this direction have been formulated, model simulations are on-going and studies are being planned. EUROGIN aims to be an occasion of update and discussion on these subjects. 

Again this year, WACC (Women Against Cervical Cancer), founded in 2008, will be part of the congress. It is an initiative that aims to make cervical cancer prevention a top priority on women's and public health agendas. The essence of WACC is embodied in five missions: to inform, to gather, to educate, to work together and, most importantly, to take action! 

We therefore invite you to Florence to participate in this year's EUROGIN congress to stay “up to date” in the field of HPV infection. Twelve years ago, our main goal, beside cervical cancer prevention, was the treatment of vulvar warts. Today, our attention covers not only female lower genital tract infections and lesions, but also anal, penile, and head and neck lesions both in men and women. You should come to be able to bring back to your institution the most recent knowledge about HPV and to meet over 2000 colleagues, researchers, speakers who are participating in lively discussions. 

Finally, we hope that you will enjoy your stay in the beautiful city of Florence!

Speakers/Faculty:
Alemany Laia Spain
Antilla Ahti Finland
Arbyn Marc Belgium
Baussano Iacopo France
Belinson Jerome USA
Bergeron Christine France
Berkhof Hans The Netherlands
Bogaards Johannes The Netherlands
Bogers John-Paul Belgium
Boily Marie-Claude UK
Bonanni Paolo Italy
Bonardel Gérald France
Bonde Jesper Denmark
Bornstein Jacob Israel
Bosch Xavier Spain
Brakenhoff Ruud The Netherlands
Brisson Marc Canada
Brotherton Julia Australia
Burtness Barbara USA
Carozzi Francesca Italy
Castellsagué Xavier Spain
Chaturvedi Anil USA
Clifford Gary France
Cortes Javier Spain
Cruickshank Margaret UK
Crum Christopher USA
Cuschieri Kate UK
Cuzick Jack UK
Dalianis Tina Sweden
Deutsch Eric France
Dexeus Santiago Spain
Dillner Joakim Sweden
Doorbar John UK
D'Souza Gypsyamber USA
Einstein Mark USA
Fakhry Carole USA
Franceschi Silvia France
Franco Eduardo Canada
Fromm Tanja Germany
Garland Suzanne Australia
Gertig Dorota Australia
Gillison Maura USA
Giuliano Anna USA
Goldstone Stephen USA
Goodman Marc USA
Gross Gerd Germany
Grulich Andrew Australia
Haie-Meder Christine France
Harper Diane USA
Heideman Danielle The Netherlands
Herfs Michael USA
Huh Warner USA
Iftner Thomas Germany
Ikenberg Hans Germany
Iversen Ole Erik Norway
Jit Mark UK
Joura Elmar Austria
Kaufmann Andreas Germany
Kreimer Aimée USA
Lacau St Guily Jean France
Lacey Charles UK
Lefebvre Jean-Louis France
Lehtinen Matti Finland
Licitra Lisa Italy
Lopalco Pierluigi Sweden
Lorenzon Laura Italy
Lorincz Attila UK
Lu Beibei USA
Maggino Tiziano Italy
Mai Verna Canada
Malagon Talia Canada
Martinon-Torres Federico Spain
Mehanna Hisham UK
Meijer Chris The Netherlands
Moscicki Anna-Barbara USA
Mullerat Pepe UK
Neels Pieter Belgium
Nielsen Karsten Denmark
Nyitray Alan USA
Oguejiofor Ken UK
Paavonen Jorma Finland
Pai Sarah USA
Palefsky Joel USA
Pawlita Michael Germany
Pitts Marian Australia
Poetter R. Austria
Poljak Mario Solvenia
Pretorius Robert USA
Reuschenbach Miriam Germany
Rischin Danny Australia
Roberts Sally UK
Ronco Guglielmo Italy
Roy Michel Canada
Safaeian Mahboobeh USA
Salisbury David UK
Sankaranarayanan Rengaswamy France
Schlecht Nicolas USA
Shroyer Ken USA
Sideri Mario Italy
Singer Albert UK
Smith Jennifer USA
Snijders Peter The Netherlands
Stanley Margaret UK
Steben Marc Canada
Steenbergen Renske The Netherlands
Stoler Mark USA
Syrjänen Stina Finland
Syrjänen Kari Finland
Szarewski Anne UK
Tabrizi Sepehr Australia
Tachezy Ruth Czech Rep.
Unger Elizabeth USA
Van de Velde Nicolas Canada
Van der Burg Sjoerd The Netherlands
Vänskä Simopekka Finland
von Knebel Doeberitz Magnus Germany
Wang Susan Switzerland
Wentzensen Nicolas USA
Wisman Bea The Netherlands
Wright Tom USA
Registration Not yet available Register Now
Accommodation
Accommodation:

The EUROGIN congress organizers have set aside a large number of hotel rooms in many different hotels in Florence (3-star, 4-star and 5 stars categories).

NeT Congress & Education is the official housing office and will be pleased to assist you with hotel bookings. Below is a list with all hotels we can offer, including rates, position in the city and distance to the congress centre. In case you wish to make a group reservation, please contact directly Net Congress & Education . Reservations with more than 10 rooms booked will be considered as group reservations and reduced reservation fees will apply.

For reservations and enquiries, please contact: 

Organizing Secretariat 

  • Dalia Hason
  • Net Congress & Education SPA
  • Via Privata Alessandro Antonelli 3
  • 50019 Sesto Fiorentino,
  • Florence - Italy

  • Tel. +39/ 02.87387242 Fax: +39.02.91434069
  • Email: eurogin2013@netcongresseducation.com



Scientific Content Up to Date
Scientific Program:
Submission Info

General Conditions for Submission of Abstracts 

  • Submission of an abstract implies the commitment that the presenting author registers for the Eurogin 2013 congress and that financial resources to attend are available.
  • Authors are requested to register within 10 days after having received their provisional notification of acceptance. Abstracts of authors not registered by July 19, 2013 will not be taken into consideration for the final program. For special cases like group registrations, please contact the EUROGIN secretariat atadmin@eurogin.com
  • Abstracts must be submitted and presented in ENGLISH.
  • Abstracts should be prepared as a WORD document in accordance with the editing instructions below, and sent by email to the EUROGIN organizing committee at the following address: 

    admin@eurogin.com
    Abstracts that do not comply with the editing instructions will not be considered. 

  • For Free Communications or Poster sessions, only ONE abstract can be submitted per person (presenter).
  • Original scientific material is welcome and preference is given to recent findings not published yet at the date of the congress.
  • Abstracts will be peer reviewed and classified by experts in one of the categories (topics) listed; they will be allocated for oral or poster presentation. Authors who do not wish to be considered for oral presentation are requested to indicate this when submitting. However, please note, that the Scientific Committee will make the final decision for the mode of presentation.
  • The final decision of the Scientific Committee will be announced before July 19, 2013.
  • Authors agree that their abstract will be published in an Abstract Book which will be provided to all registered participants of the congress.
  • All accepted abstract authors will receive confirmation by email. Please do not forget to indicate your correct email address and telephone number when submitting your abstract.
  • Most accepted abstracts will be allocated for poster presentation. Detailed technical instructions will be made available to the authors in due time.
  • All accepted abstracts will be published in the final abstract book of the conference.



Abstract Editing Instructions 

  • Format: WORD file.
    • Maximum number of characters: 2,200, not counting spaces, but including title and accreditations.
    • Use Arial font size 11
    • The title must be written in UPPER CASE (capitals) and bold; (keep it brief, clearly indicating the nature of the investigation. It should not exceed 2 lines).
    • Please avoid complex mathematical formulae.
    • Abstracts should be structured in three sections, clearly mentioned as such: objectives – methods - conclusions.
  • Authors should be listed by their LAST NAME (family name) followed by initials of the first name only (do not include full first names). ONE author must be identified as PRESENTER by underlining of his name.
  • Give professional address for all authors: name of hospital, unit or laboratory, city and country in lower case. No other indications are to be given. If different affiliations, please use numbers.
  • Do not indent spaces on the first line of each paragraph. Abstracts should be typed single spaced, with no space between paragraphs. Use international standards for scientific articles.
  • Only standard abbreviations may be used without definition. Data must be given in units widely used in literature.
  • Only essential references should be included and put in brackets at the end of the abstract: numbers in the text may refer to them.
  • Drugs must be identified by their generic names.



Abstract Topics 

For review purposes, abstracts are classified according to the following list. Select only 1 topic that best characterizes your abstract: 

  1. Viral and molecular biology
  2. Epidemiology and natural history
  3. Pathogenesis
  4. Immunology
  5. HPV prophylactic vaccines: clinical aspects
  6. HPV prophylactic vaccines: basic science
  7. HPV therapeutic vaccines
  8. HPV testing
  9. Genotyping
  10. Molecular markers
  11. Screening methods
  12. Liquid based cytology
  13. Automation in cytology
  14. New technologies
  15. Diagnostic procedures
  16. Colposcopy
  17. Cervical neoplasia
  18. Vaginal neoplasia
  19. Vulvar diseases and neoplasia
  20. Anal neoplasia
  21. Oral HPV infection
  22. HPV and oropharynx / Head and neck cancer
  23. HPV and associated skin diseases
  24. HPV and other neoplasia
  25. Genital warts
  26. Sexually transmitted diseases and HIV infection
  27. Conventional therapies
  28. New treatments - Immunotherapy
  29. Economics and modelling
  30. Advocacy, acceptability and psychology
  31. Health education
  32. Low resource settings
Sponsors Exhibitors
Sponsors / Supporters

he EUROGIN organizing committee would like to thank the following companies for their support of the congress:

Platinum Sponsors
Roche Diagnostics

 

 

Gold Sponsors

 

Silver Sponsors

 

Bronze Sponsors

Sponsors

 

Exhibitors

Exhibition Floor plans
Contact
Organising Agency

Contact: Leonardo Visani , Registration Office , NeT Congress & Education

Phone: 011-39-55-336-1340

Fax: 011-39-55-303-3895

Official Event Webpage
Event map
Revelant Events